Home › NDC Lookup › RxCUI directory › RxCUI 1988785

{23 (brigatinib 180 MG Oral Tablet) / 7 (brigatinib 90 MG Oral Tablet) } Pack — RxCUI 1988785

RxNorm drug concept · Generic pack
RxCUI 1988785 Generic pack · GPCK ● Current RxNorm concept 4 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1988785
Official name{23 (brigatinib 180 MG Oral Tablet) / 7 (brigatinib 90 MG Oral Tablet) } Pack
Concept typeGeneric pack (GPCK)
RxNorm statusCurrent RxNorm concept
FDA products mapped4
Package NDCs mapped5
Reported Medicaid activity (SDUD)144 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Brigatinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Alunbrig is used to treat a specific type of lung cancer called ALK-positive metastatic non-small cell lung cancer (NSCLC). The 'ALK-positive' part means your tumor has a genetic c...
  • That step-up approach is intentional and built into how Alunbrig is prescribed. One of the more serious early risks with this medicine is lung inflammation — sometimes called pneum...
  • Why do I have to start at a lower dose before going to the full dose?
  • The most common day-to-day side effects include diarrhea, fatigue, nausea, rash, cough, muscle aches, headache, and high blood pressure. Those are worth mentioning at your next app...
📖 Read our full Brigatinib guide →

🕸️ Concept Web — How {23 (brigatinib 180 MG Oral Tablet) / 7 (brigati... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept {23 (brigatinib 180 MG Oral Tablet) / 7 (brigatinib 90 MG Oral Tablet) } Pack RxCUI 1988785

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Brigatinib 1921217
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Alunbrig 1921223
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Brigatinib Oral Tablet 1921221
    • Brigatinib Oral Product 1921219
    • Brigatinib Pill 1921220
    • Brigatinib Oral Tablet [Alunbrig] 1921225
    • Alunbrig Oral Product 1921226
    • Alunbrig Pill 1921227
    • Pack 746839
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 8

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 1

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 19 of 20 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

📦 FDA Products & Package NDCs

4 products · 5 package NDCs
5 package NDCs map to RxCUI 1988785 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
63020-0090-07 7 TABLET, FILM COATED in 1 BOTTLE (63020-090-07) Alunbrig Takeda Pharmaceuticals America, Inc. 2017-10-02
63020-0090-30 30 TABLET, FILM COATED in 1 BOTTLE (63020-090-30) Alunbrig Takeda Pharmaceuticals America, Inc. 2017-10-02
63020-0113-30 30 TABLET, FILM COATED in 1 BOTTLE (63020-113-30) Alunbrig Takeda Pharmaceuticals America, Inc. 2017-10-02
63020-0180-30 30 TABLET, FILM COATED in 1 BOTTLE (63020-180-30) Alunbrig Takeda Pharmaceuticals America, Inc. 2017-10-02
63020-0198-30 1 KIT in 1 CARTON (63020-198-30) * 7 TABLET, FILM COATED i... Alunbrig Takeda Pharmaceuticals America, Inc. 2017-10-02
Observed labelers: Takeda Pharmaceuticals America, Inc. (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.